For the first time in recorded history, seven out of ten Americans diagnosed with cancer now survive at least five years. The milestone reflects decades of scientific investment, earlier detection, and a generation of treatments that have fundamentally changed what a cancer diagnosis means.
The American Cancer Society released its Cancer Statistics 2026 report in January, and the headline figure has drawn attention across the medical community: for the first time, the five-year relative survival rate for all cancers combined has reached 70% for people diagnosed during 2015–2021 in the United States. That number sits in stark contrast to where the country stood five decades ago. In the mid-1970s, the survival rate was 49% — meaning fewer than half of patients could expect to live five years beyond their diagnosis.
The report marks the 75th consecutive year the American Cancer Society has compiled and analyzed national cancer data, making this particular milestone meaningful not just as a single data point, but as the culmination of a long arc of progress.
From a Coin Toss to a Chronic Disease
Rebecca Siegel, senior scientific director of surveillance research at the American Cancer Society and lead author of the report, described the shift this way: “Seven in 10 people now survive their cancer five years or more, up from only half in the mid-70s. This stunning victory is largely the result of decades of cancer research that provided clinicians with the tools to treat the disease more effectively, turning many cancers from a death sentence into a chronic disease.”
That framing — from death sentence to chronic disease — captures the real-world meaning of the statistics. For millions of patients, cancer no longer signals an immediate end. It has become something to be managed, monitored, and, in a growing number of cases, eliminated entirely.
The cancer mortality rate continued to decline through 2023, averting 4.8 million deaths since 1991, largely because of smoking reductions, earlier detection, and improved treatment. The report also documents that five-year survival for distant-stage, or metastatic, cancer has doubled — from 17% in the mid-1990s to 35% today — a shift that reflects the direct impact of newer therapies.
The Cancers That Changed Most
The gains are not evenly distributed, and some of the most striking numbers come from cancers that were considered nearly untreatable just a generation ago.
Survival gains since the mid-1990s are especially notable for people diagnosed with more fatal cancers, such as myeloma, which improved from 32% to 62%, liver cancer from 7% to 22%, and lung cancer from 15% to 28%.
Lung cancer, which has historically carried among the worst prognoses in oncology, represents one of the most dramatic examples of progress. Survival for advanced lung cancer, which three in four patients are diagnosed with, has increased from 20% to 37% for regional-stage disease and from 2% to 10% for distant-stage disease. While these numbers remain sobering relative to other cancers, the trajectory marks a fundamental departure from the near-universal fatality rates of previous decades.
Metastatic melanoma tells a similarly encouraging story. Five-year survival for melanoma at the distant stage has doubled, from 16% to 35%, a gain directly attributed to immune checkpoint inhibitors — a class of immunotherapy drugs that help the body’s own immune system recognize and attack cancer cells.
What Is Driving the Gains
Rebecca Siegel, the lead author, attributed the progress clearly: “Now we have 70% of people who are diagnosed reaching that milestone five-year mark. It’s really been driven by progress over the past 30 years, particularly in terms of more targeted treatment and immunotherapies.”
Two forces have converged to produce this outcome. The first is earlier detection. Improvements in screening technologies — from colonoscopies to low-dose CT scans for lung cancer — have allowed clinicians to catch cancers at stages when treatment is more effective and outcomes are meaningfully better. Localized lung cancer has a 65% five-year survival rate compared to 10% for distant-stage disease, underscoring how dramatically stage at diagnosis shapes the odds.
The second force is treatment innovation. Immunotherapy, targeted therapies, and precision medicine have fundamentally changed the pharmacological toolkit available to oncologists. Rather than applying broad treatments like traditional chemotherapy to all tumor types, clinicians can now match therapies to the genetic and molecular profile of individual cancers — improving both effectiveness and tolerability.
The Cancer Research Institute notes that the immunotherapy revolution was built on decades of basic science funded by institutions like the National Cancer Institute and philanthropic organizations committed to cancer immunology research. The gains documented in the 2026 report represent the downstream payoff of that sustained investment.
Where Work Remains
The 70% figure is a national average, and the report is explicit that it masks significant variation — both by cancer type and by population.
Pancreatic cancer survival remains at 13%, meaning patients diagnosed today face essentially unchanged odds compared to prior decades. Uterine corpus cancer mortality has been rising for 26 consecutive years. These figures serve as a reminder that the same research investments that improved outcomes for melanoma and myeloma have not yet translated into comparable gains for all tumor types.
Disparities by race and ethnicity also persist. Native American people have the highest cancer mortality, including death rates approximately two times those of White people for cancers of the kidney, liver, stomach, and uterine cervix. The report attributes these gaps primarily to barriers in access to high-quality care, including health insurance coverage, proximity to specialized cancer centers, and systemic inequities in screening and treatment delivery.
Ahmedin Jemal, senior vice president of surveillance, prevention, and health services research at the American Cancer Society, stated: “Lack of access to high-quality cancer care and socioeconomics continues to play a significant role in persistent racial disparities. Efforts need to be focused on these areas so successful targeted cancer control interventions can be more broadly and equitably applied to all populations.”
The Road Ahead
In 2026, approximately 2,114,850 new cancer diagnoses are projected to occur in the United States — roughly 5,800 each day — and 626,140 people are expected to die from the disease. Lung cancer will remain the leading cause of cancer death, claiming more lives than colorectal and pancreatic cancer combined.
The American Cancer Society has also raised concerns about the potential impact of proposed federal cuts to cancer research funding and health insurance access on future progress. The 70% milestone was built over 50 years of sustained institutional investment. The risk, researchers warn, is that disruptions to that pipeline could slow the pace of future gains at the precise moment when the science is positioned to push survival rates higher still.
As Columbia University oncologist Dawn Hershman put it: “This is tangible proof that research saves lives. Several troubling trends persist, but the overall arc is clear — we are increasingly able to transform cancer from what was once often a death sentence into a chronic condition that many people can live with for years.”
Disclamier: This article is for informational purposes only and does not constitute medical advice. Readers should consult a licensed healthcare provider for guidance on cancer screening, prevention, and treatment options.
